Sign in or create an account to add this stock to your watchlist.
About Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400
Debt
Debt-to-Equity RatioN/A
Current Ratio1.94
Quick Ratio1.72
Price-To-Earnings
Trailing P/E Ratio8.66
Forward P/E Ratio-13.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$30.77 million
Price / Sales73.89
Cash Flow$3.1164 per share
Price / Cash10.14
Book Value$1.28 per share
Price / Book24.69
Profitability
EPS (Most Recent Fiscal Year)$3.65
Net Income$-197,480,000.00
Net Margins-515.27%
Return on Equity-239.94%
Return on Assets-117.61%
Miscellaneous
Employees145
Outstanding Shares71,950,000
Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics (NASDAQ:HRTX) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.06. The biotechnology company earned $11.60 million during the quarter, compared to analyst estimates of $11.10 million. Heron Therapeutics had a negative return on equity of 239.94% and a negative net margin of 515.27%. Heron Therapeutics's quarterly revenue was up 222.2% on a year-over-year basis. View Heron Therapeutics' Earnings History.
What price target have analysts set for HRTX?
12 brokerages have issued 1-year target prices for Heron Therapeutics' shares. Their predictions range from $22.00 to $56.00. On average, they anticipate Heron Therapeutics' share price to reach $38.0833 in the next year. View Analyst Ratings for Heron Therapeutics.
What are Wall Street analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)
- 2. Mizuho analysts commented, "We believe the results demonstrate the superior product profile of HTX-011 in post-operative pain management compared to the current standard of care. We raise our PT from $28 to $35." (3/19/2018)
- 3. Cantor Fitzgerald analysts commented, "Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization." (1/15/2018)
- 4. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2018)
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Dr. Barry D. Quart, Chief Exec. Officer and Director (Age 61)
- Mr. Robert H. Rosen, Pres and Director (Age 62)
- Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
- Mr. Robert E. Hoffman CPA, Chief Financial Officer and Sr. VP of Fin. (Age 52)
- Mr. David L. Szekeres, Sr. VP - Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)
Has Heron Therapeutics been receiving favorable news coverage?
Media headlines about HRTX stock have trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heron Therapeutics earned a news sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Heron Therapeutics' major shareholders?
Heron Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (12.02%), Franklin Resources Inc. (9.79%), BlackRock Inc. (4.88%), Eagle Asset Management Inc. (2.52%), Rubric Capital Management LP (2.10%) and Highland Capital Management LP (2.07%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.
Which institutional investors are selling Heron Therapeutics stock?
HRTX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Rubric Capital Management LP, JPMorgan Chase & Co., Asymmetry Capital Management L.P., C WorldWide Group Holding A S, Fisher Asset Management LLC, Old West Investment Management LLC and Great West Life Assurance Co. Can. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart and Kimberly Manhard. View Insider Buying and Selling for Heron Therapeutics.
Which institutional investors are buying Heron Therapeutics stock?
HRTX stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Nexthera Capital LP, Rock Springs Capital Management LP, Tang Capital Management LLC, UBS Group AG and Cohen Capital Management Inc.. View Insider Buying and Selling for Heron Therapeutics.
How do I buy shares of Heron Therapeutics?
Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
One share of HRTX stock can currently be purchased for approximately $31.60.
How big of a company is Heron Therapeutics?
Heron Therapeutics has a market capitalization of $2.25 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.
How can I contact Heron Therapeutics?
Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]
MarketBeat Community Rating for Heron Therapeutics (HRTX)
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Heron Therapeutics (NASDAQ:HRTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Heron Therapeutics in the last 12 months. Their average twelve-month price target is $38.0833, suggesting that the stock has a possible upside of 20.52%. The high price target for HRTX is $56.00 and the low price target for HRTX is $22.00. There are currently 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $38.0833 | $37.4167 | $31.00 | $29.80 |
| Price Target Upside: | 20.52% upside | 20.12% upside | 29.71% upside | 82.26% upside |
Heron Therapeutics (NASDAQ:HRTX) Consensus Price Target History
Heron Therapeutics (NASDAQ:HRTX) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Heron Therapeutics (NASDAQ:HRTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Heron Therapeutics (NASDAQ HRTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.93%
Heron Therapeutics (NASDAQ HRTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/29/2018 | Kevin C Tang | Director | Buy | 192,308 | $26.00 | $5,000,008.00 | |  |
| 3/19/2018 | Barry D Quart | CEO | Sell | 100,000 | $29.75 | $2,975,000.00 | 167,993 | |
| 3/19/2018 | Kimberly Manhard | VP | Sell | 18,000 | $30.00 | $540,000.00 | 18,000 | |
| 3/14/2018 | Barry D Quart | CEO | Sell | 100,000 | $24.75 | $2,475,000.00 | 167,993 | |
| 1/10/2018 | Kimberly Manhard | VP | Sell | 7,584 | $20.00 | $151,680.00 | 7,584 | |
| 4/24/2017 | Kimberly Manhard | VP | Sell | 21,542 | $15.33 | $330,238.86 | 5,250 | |
| 1/19/2017 | Kevin C Tang | Director | Buy | 2,459,016 | $12.20 | $29,999,995.20 | | |
| 8/10/2016 | Robert Rosen | Insider | Sell | 100,000 | $23.30 | $2,330,000.00 | 102,640 | |
| 4/21/2016 | Robert Rosen | President | Sell | 200,000 | $23.23 | $4,646,000.00 | 178,968 | |
| 6/10/2015 | Kevin C Tang | Director | Buy | 121,212 | $24.75 | $2,999,997.00 | | |
| 6/2/2015 | Kevin C Tang | Director | Buy | 150,000 | $20.62 | $3,093,000.00 | | |
| 6/1/2015 | Kimberly Manhard | Director | Sell | 2,708 | $21.17 | $57,328.36 | | |
| 6/25/2014 | Barry D Quart | CEO | Buy | 10,000 | $11.75 | $117,500.00 | | |
| 6/25/2014 | Kevin C Tang | Director | Buy | 510,638 | $11.75 | $5,999,996.50 | | |
| 11/20/2013 | Barry D Quart | CEO | Buy | 1,000,000 | $0.40 | $400,000.00 | | |
(Data available from 1/1/2013 forward)
Heron Therapeutics (NASDAQ HRTX) News Headlines
| Source: |
|
Heron Therapeutics (NASDAQ:HRTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Heron Therapeutics (NASDAQ:HRTX) Income Statement, Balance Sheet and Cash Flow Statement
Heron Therapeutics (NASDAQ HRTX) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
